<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">medalphabet-449</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Искусство подбора противомигренозной терапии. Лечение приступа мигрени</article-title><trans-title-group xml:lang="en"><trans-title>Art of selecting antimigrenous therapy. Treatment of migraine attack</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeev</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>клиника «Чайка»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First Moscow State Medical University n.a. I. M. Sechenov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>10</day><month>01</month><year>2018</year></pub-date><volume>1</volume><issue>1</issue><issue-title>Неврология и психиатрия</issue-title><fpage>26</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сергеев А.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Сергеев А.В.</copyright-holder><copyright-holder xml:lang="en">Sergeev A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/449">https://www.med-alphabet.com/jour/article/view/449</self-uri><abstract><p>Терапия пациентов с мигренью недостаточно эффективна. Противомигренозные средства купируют два приступа из трех. При этом низкий обезболивающий эффект часто связан с несоблюдением правил применения лекарственных средств и недооценкой эффективности немедикаментозных методов профилактической терапии. Среди специалистов и пациентов сохраняются необоснованные опасения по безопасности использования триптанов как основной патогенетической терапии приступа мигрени. Неправильное использование неспецифической терапии в виде простых аналгетиков и НПВП, особенно при тяжелых приступах, приводит к снижению эффективности лечения, увеличению длительности мигренозных атак и к избыточному приему анальгетиков. Обзор посвящен практическим рекомендациям по эффективной терапии как болевого синдрома, так и ассоциированных симптомов приступа мигрени.</p></abstract><trans-abstract xml:lang="en"><p>Acute migraine treatment is challenging. Migraine medications are effective in two out of the three attacks only. Individual response to an analgesics is difficult predictable. Migraine attack treatment is often ineffective on account of non-compliance with the rules for the use of analgesics. Acute migraine medications should be used as early as possible after the onset of headache phase. The effective choice for a migraine patient depends on the severity of the attacks, associated symptoms particularly nausea and vomiting, comorbid disorders, and the individual patient's response. A stratified approach based on the patient’s therapeutic needs has been discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мигрень</kwd><kwd>приступ</kwd><kwd>практические рекомендации</kwd><kwd>триптаны</kwd><kwd>суматриптан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>migraine</kwd><kwd>acute therapy</kwd><kwd>triptans</kwd><kwd>stratified approach</kwd><kwd>sumatriptan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014. Jan 8; 15:3.</mixed-citation><mixed-citation xml:lang="en">Steiner TJ, Gururaj G, Andrée C, Katsarava Z, Ayzenberg I, Yu SY, Al Jumah M, Tekle-Haimanot R, Birbeck GL, Herekar A, Linde M, Mbewe E, Manandhar K, Risal A, Jensen R, Queiroz LP, Scher AI, Wang SJ, Stovner LJ. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014. Jan 8; 15:3.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017 Dec; 18 (1): 34.</mixed-citation><mixed-citation xml:lang="en">Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017 Dec; 18 (1): 34.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева Г. Р. Рациональная комбинированная терапия приступа мигрени. Consilium medicum. 2013.-N9.-С. 18-23.</mixed-citation><mixed-citation xml:lang="en">Табеева Г. Р. Рациональная комбинированная терапия приступа мигрени. Consilium medicum. 2013.-N9.-С. 18-23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Сергеев А. В. Доказательная терапия приступа мигрени. Consilium Medicum. Неврология и ревматология. (Прил.) 2015; 01: 34-37.</mixed-citation><mixed-citation xml:lang="en">Сергеев А. В. Доказательная терапия приступа мигрени. Consilium Medicum. Неврология и ревматология. (Прил.) 2015; 01: 34-37.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www. ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November25, 2013).</mixed-citation><mixed-citation xml:lang="en">Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www. ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November25, 2013).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Первичные головные боли. Практическое руководство. / В. В. Осипова, Г. Р. Табеева. -М.:, ООО «ПАГРИ-Принт», 2007.-60 с.</mixed-citation><mixed-citation xml:lang="en">Первичные головные боли. Практическое руководство. / В. В. Осипова, Г. Р. Табеева. -М.:, ООО «ПАГРИ-Принт», 2007.-60 с.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sândor PS. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 Sep; 16 (9): 968-81.</mixed-citation><mixed-citation xml:lang="en">Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sândor PS. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009 Sep; 16 (9): 968-81.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.</mixed-citation><mixed-citation xml:lang="en">Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ 2014; 348: g 2285.</mixed-citation><mixed-citation xml:lang="en">Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ 2014; 348: g 2285.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 2015; 35: 118.</mixed-citation><mixed-citation xml:lang="en">Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 2015; 35: 118.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563.</mixed-citation><mixed-citation xml:lang="en">Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Christoph-Diener H, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004; 63: 520.</mixed-citation><mixed-citation xml:lang="en">Christoph-Diener H, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004; 63: 520.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19.</mixed-citation><mixed-citation xml:lang="en">Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">BET 1: Metoclopramide or prochlorperazine for headache in acute migraine? Emerg Med J 2013; 30: 595.</mixed-citation><mixed-citation xml:lang="en">BET 1: Metoclopramide or prochlorperazine for headache in acute migraine? Emerg Med J 2013; 30: 595.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шагбазян А.Э., Сергеев А. В., Евдокимова Е. М., Курбанбагамаева Р. Р., Табеева Г. Р. Роль эмоциональных и поведенческих расстройств в формировании лекарственной зависимости у пациентов с медикаментозно-индуцированной головной болью (обзор). Неврология, нейропсихиатрия, психосоматика. 2016; 8 (3): 76-81.</mixed-citation><mixed-citation xml:lang="en">Шагбазян А.Э., Сергеев А. В., Евдокимова Е. М., Курбанбагамаева Р. Р., Табеева Г. Р. Роль эмоциональных и поведенческих расстройств в формировании лекарственной зависимости у пациентов с медикаментозно-индуцированной головной болью (обзор). Неврология, нейропсихиатрия, психосоматика. 2016; 8 (3): 76-81.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 1359.</mixed-citation><mixed-citation xml:lang="en">Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 1359.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
